382 results about "Liver function" patented technology

The invention provides a preparation method of cereal fermentation broth postbiotics and application of the cereal fermentation broth postbiotics in improvement of systemic chronic inflammation and reduction of cholesterol and low-density lipoprotein, and belongs to the technical field of fermentation engineering. The invention provides a preparation method of cereal fermentation broth metabiotics, which is characterized in that mixed cereals are used as raw materials, anaerobic fermentation is carried out by using compound enzymes and various bacteria, and polysaccharides and proteins in the cereal raw materials can be quickly converted into functional small molecular substances, such as polypeptides, total phenols and total flavonoids. The cereal fermentation broth metagen can inhibit secretion of a macrophage proinflammatory medium, inhibit generation of inflammatory factors of liver, heart and intestinal tissues, and improve activation of adipose tissue macrophages related to body inflammation. After the cereal fermentation liquor is subjected to post-biogen treatment, glucose and lipid metabolism disorder can be effectively improved, liver function damage can be relieved, and the intestinal barrier function can be effectively improved.

The invention provides a liver function prediction method and device, electronic equipment and a medium, and the method comprises the steps: obtaining original clinical data of a plurality of pneumonia patients, and grouping an original clinical database according to the liver injury degree; performing significance evaluation on characteristic variables in the data, and finding out a first characteristic variable related to the liver injury degree; extracting a first feature variable in the data, and constructing a first data set; respectively training and evaluating the plurality of machine learning models, and selecting the machine learning model with the optimal evaluation result as a liver function prediction model; carrying out interpretability analysis on the liver function prediction model; extracting a second feature variable in each piece of original clinical data to construct a second data set; training a liver function prediction model based on the second data set to obtain a trained liver function prediction model; and predicting the liver function of the target pneumonia patient based on the trained liver function prediction model. The method can be used for rapidly predicting the liver function of the pneumonia patient.

The invention provides a multi-channel one-core multi-detection integrated detection method, which is applied to the technical field of in-vitro diagnosis and comprises the following steps: acquiring time sequence original signals of blood routine, liver function and kidney function channels; obtaining a baseline stable primary signal through cross-channel baseline trend coupling and adaptive correction; adopting a machine learning model to identify interference components and performing component offset to obtain a decoupling signal; mapping the decoupling signal into a physiological parameter value and carrying out rationality test; when the low credible parameter exists, a rechecking mechanism is triggered; performing weighted fusion on the basis of the rationality test result and the recheck signal to obtain a comprehensive parameter set; and finally generating a comprehensive detection report containing the credibility score. Cooperative processing and fusion analysis of multi-channel detection signals are realized, and the accuracy and reliability of a detection result are remarkably improved through interference identification and a dynamic recheck mechanism.

The present invention relates to pro-nano-emulsion compositions comprising at least one type of Omega 3 fatty acid capable of converting to nano-emulsion composition having average droplet size of below Ip, typically below 0.5p, and use thereof, particularly as dietary supplement, for preferential delivery of the Omega 3 fatty acid to heart and / or liver tissue of a subject consuming the composition, thereby maintaining normal cardiovascular / hepatic function and / or improving cardiovascular / hepatic disease or disorders.

The invention relates to the technical field of data processing, and discloses an old-age multi-organ function decline rehabilitation prediction method and system based on artificial intelligence. The method comprises the following steps: screening cardiovascular, respiratory, renal function and liver function indexes of an elderly patient through a multi-source data quality evaluation matrix, carrying out time sequence synchronization according to visceral organ physiology time delay characteristics, adopting a visceral organ function correlation positioning analysis algorithm to identify a collaborative decline mode and calculating 1-NN similarity and Max-NN correlation decline degree, and finally, inputting target patient data into a special prediction model of a corresponding hierarchical group to generate a rehabilitation prediction result. According to the method and the device, the technical problem that an existing senile multi-organ function decline prediction method lacks parameter-free collaborative decline mode recognition and individualized layered prediction is solved.

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

The invention provides a preparation method and application of a turmeric extracellular vesicle targeted drug delivery system with an anti-colon cancer effect. The engineering system of modifying CELNs and loading DOX by the TCP-1 colon cancer targeting peptide is constructed by extracting curcuma longa extracellular vesicles (CELNs). The system of loading adriamycin through targeted modified turmeric extracellular vesicles has better anti-tumor activity and tumor targeting property, and HE staining and serum detection results show that the system has no significant influence on important tissues, visceral organs and liver functions of mice. And the biological safety is improved while a better treatment effect is achieved.

The invention provides a liver function data detection method and system for liver cancer high-risk groups, and relates to the field of health management. Context snapshots based on user IDs are created and updated in real time in a high-speed memory cache region, and a user diagnosis type, a medication state and a medication timestamp are combined to detect the liver function data of the liver cancer high-risk groups. According to the method and the device, the liver function data is subjected to differential judgment on the basis of the preset logic tree, so that the problems of misinformation and missing report caused by lack of context information in the prior art are effectively solved, the liver function data can be subjected to differential judgment accurately in real time according to the diagnosis type and the medication state of the user, misinformation and missing report are effectively avoided, and the user experience is improved. And the accuracy and the reliability of the alarm system are improved.

The invention discloses a liver, gall and pancreas patient symptom evaluation system based on multi-dimensional data, and relates to the technical field of liver, gall and pancreas symptom evaluation. The visual management platform is in communication connection with a data acquisition module, an abnormal symptom classification module, a symptom risk analysis module, a symptom risk classification module and a report generation module, and all the modules are in electric signal connection; the data acquisition module is used for collecting and preprocessing multi-dimensional index data of a liver function index, a biliary system index and a pancreas index of a patient. By integrating the multi-dimensional data of the liver function index, the biliary system index and the pancreas index, the health condition of the liver, gall and pancreas patient can be more comprehensively reflected, compared with a traditional single-dimensional evaluation method, the abnormal symptoms of the patient can be more accurately recognized, the possibility of misdiagnosis and missed diagnosis is reduced, and the diagnosis accuracy is improved. And personalized symptom risk assessment can be carried out according to specific data of each patient, so that the medical decision is more accurate.

The invention discloses application of 2-hydroxybutyric acid and derivatives thereof in preparation of drugs for preventing and / or treating metabolic diseases, and belongs to the technical field of biological medicines. Experiments prove that the 2-hydroxybutyric acid and the derivatives thereof can effectively inhibit obesity induced by high fat diet and reduce body fat, and have good improvement effects on related glucose and lipid metabolism disorders, including reduction of fasting blood-glucose, improvement of glucose tolerance, reduction of liver lipid deposition and improvement of liver functions. More importantly, the 2-hydroxybutyric acid does not affect ingestion, the metabolism improvement effect of the 2-hydroxybutyric acid depends on activation of fat heat production, and energy consumption can be directly promoted, so that obvious gastrointestinal tract adverse reactions cannot be generated, and potential mental side effects of existing appetite inhibiting drugs do not exist.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing and / or treating biliary atresia. The new application of ganoderic acid A in preparation of drugs for preventing and / or treating biliary atresia is found for the first time. The method comprises the following steps: within 24 hours after a BALB / c newborn mouse is born, inducing the formation of BA by intraperitoneal injection of RRV, and from the second day after intraperitoneal injection of RRV, carrying out intraperitoneal injection of Ganoderic Acid A on the mouse every day until the twelfth day, it can be observed that the survival time of BA mice treated by the Ganoderma Acid A is prolonged, the weight loss is obviously improved, the jaundice symptom is relieved, the liver function index is obviously improved, the infiltration number of inflammatory cells around the intrahepatic bile duct is obviously reduced, and the liver bile duct injury is relieved. The invention provides a new potential target and a treatment strategy for treatment of BA, and has potential clinical treatment significance.

Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.

The invention discloses an application of a pyroptosis inhibitor in preparation of a product for treating biliary atresia, the pyroptosis inhibitor 2-bromohexadecanoic acid has a certain treatment effect on biliary atresia mice, can significantly prolong the survival time of the mice, improve jaundice, improve the liver function of the mice, reduce the infiltration quantity of inflammatory cells around intrahepatic bile ducts, and can be used for treating the biliary atresia. A new potential target and a treatment strategy are provided for treatment of biliary atresia.

The invention belongs to the technical field of pharmacotherapeutics, and particularly relates to application of theaflavin-3 '-gallate and a medicine prepared from theaflavin-3'-gallate. The theaflavin-3 '-gallate is used as a KEAP1-NRF2 inhibitor and is competitively combined with the KEAP1 to destroy the inhibition effect of the KEAP1 on the NRF2, so that the content of the NRF2 is increased, and the expression of downstream NQO1 and GCLC is improved. Besides, the theaflavin-3 '-gallate protects the liver function by inhibiting the increase of the contents of AST and ALT, and reduces the oxidative stress and lipid accumulation of the liver, so that the theaflavin-3'-gallate has the potential to become a medicine for treating the ethanol-induced liver injury.

A microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix for liver regeneration and a preparation method. The hydrogel is prepared by means of combining fish liver decellularized extracellular matrix (dECM) and gelatin methacryloyl (GelMA), and loading induced pluripotent stem cell-derived hepatocytes (iPSC-heps) for liver regeneration. The microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix exhibits excellent biocompatibility, retains intact endogenous growth factors, maintains the biological activity of cells, ensures the effective encapsulation of the cells, and facilitates the robust functional expression of the iPSC-heps. After in-vivo transplantation, the survival rate and liver function of mice with acute liver failure are significantly improved, and liver regeneration and repair are promoted.

The invention provides an application of a composition containing a sweet osmanthus extract in preparation of a product for improving liver functions and relieving liver injury. The preparation method comprises the following specific steps: (1) naturally drying sweet osmanthus in the shade, crushing, sieving, soaking in ultrapure water, carrying out suction filtration, and collecting a sweet osmanthus extracting solution; and (2) carrying out rotary evaporation on the osmanthus fragrans extracting solution in the step (1) until yellow syrup-shaped liquid is formed, so as to form an osmanthus fragrans concentrated solution, freezing, and carrying out vacuum drying, so as to obtain the osmanthus fragrans extract. According to the composition containing the osmanthus fragrans extract, ROS and MDA indexes in liver cells damaged by DBP can be reduced, reduction of GSH indexes is relieved, meanwhile, inflammatory indexes NF-kappa B, TNF-alpha and IL-6 are reduced, it is indicated that the composition containing the osmanthus fragrans extract has the capacity of inhibiting oxidative stress and inflammation in the damaged liver cells, and the composition containing the osmanthus fragrans extract has the advantages of being capable of being used for preventing and treating liver injury. Liver function impairment caused by DBP can be remarkably relieved, the application prospect is good, and practical significance is achieved.

The application discloses an animal bifidobacterium producing bile salt hydrolase and application thereof in neonatal jaundice, and belongs to the technical field of microorganisms. The animal bifidobacterium lactis WXM screened by the application has the effect of relieving neonatal jaundice, can significantly improve weight loss of a jaundice individual in an early life stage, improve abnormal increase of a bilirubin level in serum, improve liver damage, improve the level of an enzyme related to liver function, the expression level of a related inflammatory factor in the liver and the expression level of an enzyme UGT1A1 related to bilirubin metabolism, and has the effect of relieving neonatal jaundice. The strain of the application has high safety and has wide application value in the fields of food, functional food, health products, medicine and the like.

The invention relates to a construction method of a model for preoperative evaluation of postoperative complications of hepatic resection. Performing high-order interactive modeling on the plurality of preoperative characteristic variables, and identifying the potential influence of the multi-factor joint effect on the postoperative complications; comprising the interaction between hepatic insufficiency and diabetes and the relationship between preoperative anemia and malnutrition; using a decision tree model to screen out features matched with the complication risk by calculating each variable and interaction item; for the modeling of the nonlinear relationship between the variables, capturing the nonlinear relationship between the variables by adopting a support vector machine (SVM) method; the prediction of the increase of the preoperative liver hardness is in a non-linear relationship with the risk of postoperative complications; constructing a multi-level regression model including hierarchical Bayesian regression, performing risk assessment on different levels including an individual level and a group level, and integrating individual differences and group features of patients; and each layer of model independently evaluates different risk factors, and integrates data of different layers for prediction.

The invention discloses a preparation method of crocodile liver peptide for improving liver injury, and relates to the technical field of bioactive peptide extraction, and the preparation method comprises the following steps: crocodile liver pretreatment: cutting fresh crocodile liver into blocks, mixing with deionized water, homogenizing, and adding a zirconium phosphate molecular sieve to obtain crocodile liver homogenate; enzymatic hydrolysis reaction: adjusting the pH value of the homogenate, and adding a compound enzyme preparation for enzymatic hydrolysis; carrying out enzyme deactivation treatment, namely heating, cooling, centrifuging and taking supernate; performing ultrafiltration separation, namely filtering the supernate through an ultrafiltration membrane, and collecting a small molecule peptide solution; purifying and refining: purifying through sephadex column chromatography, and freeze-drying to obtain a crocodile liver peptide product; a double-particle-size zirconium phosphate molecular sieve is constructed to cooperate with a compound enzyme preparation for enzymolysis, electron transfer is enhanced by combining phosphorylation modification, the defects of metal inhibition enzyme activity, insufficient concealed peptide fragment cutting and oxidative damage are overcome, meanwhile, the application of the crocodile liver peptide in the aspect of improving the liver function is researched, and the crocodile liver peptide has a good application prospect. And a new choice is provided for prevention and treatment of liver diseases and liver health care.

The invention discloses a biological medicine application of luwulinine, and provides and verifies that luwulinine can inhibit disulfiram death of cells for the first time, so that luwulinine can be used for preventing or treating hepatic ischemia reperfusion injury. Experimental data show that the luteiniine can relieve liver function injury after reperfusion with cell apoptosis, tissue inflammation infiltration and tissue fibrosis as manifestations, and a new direction is provided for mechanism research and prevention and treatment of hepatic ischemia reperfusion injury.

The invention relates to the technical field of albumin oligopeptides, in particular to a preparation method of albumin oligopeptides and application of the albumin oligopeptides in promotion of postoperative patient recovery. The albumin oligopeptide provided by the invention can be taken before, during or after an operation, not only can quickly promote postoperative recovery and reduce the content of total bilirubin and direct bilirubin of a patient, but also can reduce the activity of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, and also can reduce the activity of carbohydrate antigen 199 and the content of alpha fetoprotein. In addition, by taking the albumin oligopeptide, the bitter throat dryness can be improved, nausea and vomiting symptoms can be eliminated, and the albumin oligopeptide has the effect of promoting postoperative liver function recovery of obstructive jaundice.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to fermented lactobacillus mucus with an anti-aging function and application of the fermented lactobacillus mucus. The strain is preserved in Guangdong Microbial Culture Collection Center on August 27, 2025, and the preservation number is GDMCC No: 66877. Experimental results show that the bacterium has excellent oxidation resistance, can relieve oxidative damage, delay senescence and inhibit senescence-related gene expression, shows the capabilities of improving memory reproduction capability decline caused by senescence, improving body anti-inflammatory capability and improving intestinal flora imbalance induced by senescence, and can regulate fat factor level and improve energy metabolism, so that the function of resisting senescence is achieved. And the polypeptide shows the potential of resisting fat deposition and protecting liver functions. Therefore, the strain can be used for developing products with multiple beneficial functions of delaying senescence, contributing to resisting oxidation, assisting in improving memory, contributing to regulating intestinal flora and the like, has the advantages of high safety, strong gastrointestinal tract tolerance and good colonization ability, and has a very good application value.

The invention mainly relates to a composition for reducing fat and losing weight as well as a preparation method and application thereof, and belongs to the technical field of biology. The composition comprises 30-60 parts of cordyceps flower sporocarp particles, 5-20 parts of morchella sporocarp particles, 10-25 parts of tartary buckwheat powder, 10-25 parts of a mulberry leaf water extract, 5-21 parts of a rhizoma polygonati water extract and 1-6 parts of a cassia seed water extract. The raw materials are mixed to obtain the composition. The composition can improve the blood fat level of hyperlipidemia, inhibit weight increase, reduce the volume of white fat cells, inhibit liver lipid deposition, reverse liver tissue and liver function damage, effectively reduce lipid and lose weight, and play a role in treating hyperlipidemia, obesity and fatty liver.

The invention relates to the technical field of biology, and particularly discloses a Meditrraneibacter faeces strain and application of the Meditrraneibacter faeces strain in relieving of metabolism-related fatty liver diseases. The Mediterraneeibacter faeces strain found from faeces of healthy people can be applied to preventing, relieving and / or treating metabolism-related fatty liver diseases, animal experiment results show that hepatic cell fatty degeneration of mice is relieved, hepatic cell balloon-like degeneration is reduced, and hepatic cell liver-like degeneration is reduced. Therefore, the strain can improve liver fatty degeneration and inflammatory response of mice with metabolism-related fatty liver diseases. Moreover, by adopting the strain to interfere with the liver function and lipid metabolism of a mouse with the metabolism-related fatty liver disease, the levels of ALT, AST, TG, CHO and LDL in serum of the mouse with the metabolism-related fatty liver disease can be reduced.

The invention relates to application of coptis alkaloid in preparation of a medicine for down-regulating liver TREM2 expression, and belongs to the technical field of biological medicine. Animal experiments prove that the rhizoma coptidis alkaloid has the effects of improving liver pathological injury, lipid droplet deposition, liver function impairment, fatty degeneration, iron overload and inflammatory response caused by MASH, and meanwhile, the expression level of TREM2 is improved.

The present invention relates to the field of biomedicine technology, and provides the use of an upregulator of ACOT2 in promoting liver regeneration and liver function recovery after partial hepatectomy. Specifically, it provides the use of an ACOT2 expression promoter in the preparation of a drug for promoting liver regeneration and liver function recovery after partial hepatectomy, as well as a pharmaceutical composition comprising the ACOT2 expression promoter. The present invention has developed new discoveries about the function of the ACOT2 gene. The increased expression of ACOT2 after hepatectomy has a certain protective effect on liver regeneration, or can serve as a potential marker for warning the degree of postoperative liver function damage and liver regeneration capacity, and a therapeutic target for promoting postoperative liver regeneration. By using the intervention method of the present invention, the decomposition and consumption of lipid droplets in the liver lipid metabolism process are targeted, thereby promoting the recovery of liver function and liver-to-body ratio.

The invention discloses a pharmaceutical composition for improving liver dysfunction, the pharmaceutical composition comprises a tablet core and a coating film, the tablet core comprises 30-40 parts of mono-ammonium glycyrrhizinate (20-30 parts by weight of glycyrrhizin), 20-30 parts of glycine, 20-30 parts of methionine, 55-65 parts of a filler, 2-10 parts of a disintegrating agent, 1-10 parts of an adhesive and 1-10 parts of a lubricant, and the coating film is a gastric soluble film coating; wherein the filling agent is formed by compounding lactose, microcrystalline cellulose, calcium carbonate, calcium hydrophosphate and mannitol, the mass ratio of the lactose to the microcrystalline cellulose to the calcium carbonate to the calcium hydrophosphate to the mannitol is (1-24): (1-35): (1-25): (1-9): (1-9), and the pharmaceutical composition for improving liver dysfunction has good dissolution and stability.